凱普生物(300639.SZ)：“新型冠狀病毒2019-nCoV核酸檢測試劑盒(熒光PCR法)”等產品擬中選相關帶量採購
格隆匯5月9日丨 凱普生物(300639.SZ)公佈，2022年4月29日，廣東省藥品交易中心發佈的《廣東省藥品交易中心關於公示廣東聯盟新型冠狀病毒(2019-nCoV)檢測試劑和相關耗材帶量採購接續擬中選結果的通知》，將廣東聯盟新冠試劑耗材接續帶量採購擬中選結果予以公示；公示期已於2022年5月7日結束。此次帶量採購系廣東省聯合遼寧、江西、湖南、廣西、雲南、甘肅、青海、寧夏、山西、黑龍江、浙江、海南、重慶、貴州、陝西、新疆、新疆建設兵團等組成採購聯盟，對新型冠狀病毒(2019-nCoV)檢測試劑和相關耗材開展的帶量採購。
公司全資子公司潮州凱普生物化學有限公司(“凱普化學”)積極參與此次帶量採購的投標工作。據擬中選結果公示顯示，凱普化學“新型冠狀病毒2019-nCoV核酸檢測試劑盒(熒光PCR法)”等產品擬中選上述帶量採購產品分類表中的第1類採購單B普通核酸試劑及組套。
擬中選產品基本情況：
注：上述品種的中選價格及中選數量均以廣東省藥品交易中心發佈的最終數據為準。
此次廣東聯盟新冠試劑耗材接續帶量採購週期原則上自中選結果實際執行日起至2023年5月25日。對企業的中選價格聯盟地區內的醫療機構不得二次議價。中選結果的實施時間、預採購量以及採購方式等事宜，以聯盟地區各省(市、區)公佈的為準。
此次帶量採購的聯盟地區醫療機構，將優先使用此次新型冠狀病毒(2019-nCoV)檢測試劑和相關耗材帶量採購擬中選產品，並確保完成約定採購量。若公司後續簽訂購銷協議並實施，將有助於公司在聯盟十八省保持市場競爭優勢，併為持續擴大市場份額奠定基礎，進一步提升公司的品牌影響力。
上述中選產品2021年銷售收入共計約2.2億元人民幣(不包括銷售給公司旗下第三方醫學實驗室的金額，僅計算對外銷售的金額)，佔公司同期主營業務收入的8.27%。
此次帶量採購中標，雖然公司的中選產品價格與同行中選價格均有一定幅度的下降，但有助於公司在上述聯盟區域擴大市場份額奠定基礎，公司將積極利用積累的品牌優勢和市場資源，進一步促進銷售增長，保障公司未來經營業績的持續提高。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
